Friday, 20 Jul 2018

You are here

TNF Inhibitor Therapy and the Risk of Anterior Uveitis Recurrence

The TNF inhibitor drug development trials have indirectly taught us that monoclonal antibody based TNFi was capable of retarding the recurrence of anterior uveitis (AU) in patients with ankylosing spondylitis (AS).

This issue has been revisited by Swedish investigators who studied the ability of adalimumab (ADA), etanercept (ETN) and infliximab (IFX) on AU recurrence in AS patients using patients from the Swedish Rheumatology Quality Register starting their first TNFi between January 2003 to December 2010. 

The study included 1365 patients with AS.

Compared with pretreatment rates, reduced rates for AU rates were seen with ADA and IFX, while an increased AU rate was seen for ETN.

The adjusted HRs for developing AU were significantly higher for ETN versus ADA (HR: 3.86) and ETN versus IFX (HR: 1.99), while the HR for IFX versus ADA was not statistically significant.

These data confirm earlier observational studies showing the efficacy of ADA and IFX in AU. However, this study suggests little or no protection when using ETN. Suggesting mechanistic differences between antibody and receptor based therapies are clinically important in this particular extraspinal manifestation of AS.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Liver Disease Increased in Psoriasis

An observational case-control study has shown that psoriasis is associated with an increased prevalence of nonalcoholic fatty liver disease (NAFLD).

A single center, outpatient dermatology clinic studied 151 patients with psoriasis and 51 control subjects with ultrasonography to diagnose NAFLD.

Best of 2017: Cause of Death in Ankylosing Spondylitis

A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology.

They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009).

The mortality rate of AS remained stable over time.

Ixekizumab Effective in Ankylosing Spondylitis

Eli Lilly announced today the results of the COAST-W trial showing that ixekizumab (Taltz) was effective in a Phase 3 study Ankylosing Spondylitis (AS) patients who had an inadequate response or intolerance to tumor necrosis factor (TNFi) inhibitor therapy.

NPF Dietary Recommendations for Psoriatic Disease

The National Psoriasis Foundation has released dietary recommendations for adults with psoriasis and psoriatic arthritis, based on a systematic review of the current literature, with the strongest focus on weight reduction for those who are overweight or obese.

Enthesitis in PsA: A New Focus of Treatment?

Patients with psoriatic arthritis (PsA) whose disease manifestations include enthesitis showed significantly greater responses to interleukin (IL)-23 inhibition than to blocking tumor necrosis factor (TNF), suggesting the possibility that treatment decisions in the future might be guided by specific cytokine targeting.